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Abstract
Aim: To investigate the differences in leiomyoma pathophysiology by patient age at the time of surgery and
the possible signiﬁcance of postmenopausal uterine leiomyomas, particularly variants.
Methods: We retrospectively reviewed data from 471 patients who underwent surgery for uterine leiomyo-
mas and evaluated their clinical data.
Results: Overall, 441 (93.4%) women were premenopausal and 30 (6.4%) were postmenopausal. There were
no differences in the frequency of the coexistence of ovarian steroid-dependent diseases among age groups.
Common histopathological features were observed in most cases despite menopausal status; however, the
incidence of variants among postmenopausal patients was high compared to that among premenopausal
women (23.3% [7/30] vs 3.2% [14/441], respectively). Among the variant leiomyomas in postmenopausal
patients, lipoleiomyomas comprised six.
Conclusion: Although progesterone is known to play a vital role in promoting leiomyoma growth, it report-
edly performs dual actions and does not always stimulate leiomyoma growth. Our study may support the
idea that the dual action of progesterone is the primary reason for the surgical treatment required for uterine
leiomyomas in the postmenopausal period. We also found that lipoleiomyoma might be the most common
uterine leiomyoma variant requiring surgical treatment among postmenopausal women. Thus, we must con-
sider the diagnosis of uterine lipoleiomyoma in postmenopausal women with uterine leiomyomas.
Key words: menopause/hormone therapy, steroid hormones/hormone receptors/metabolism, uterine
leiomyoma/adenomyosis.
Introduction
Uterine leiomyomas, also called ﬁbroids, are common
benign reproductive tract tumors. Despite being gen-
erally benign, uterine leiomyomas are responsible for
signiﬁcant morbidity in a large proportion of women.
Uterine leiomyomas tend to appear after menarche,
grow during the reproductive years and then stabilize
or regress after menopause and affect women in their
fourth and ﬁfth decades.1 However, considerable
numbers of postmenopausal patients reportedly
undergo surgery for uterine leiomyomas.2,3 To date,
only a few studies have examined leiomyoma growth
over time and determined their signiﬁcance in the
postmenopausal period. For this reason, here we
investigated the differences in leiomyoma pathophysi-
ology by patient age at the time of surgery as well as
the possible signiﬁcance of uterine leiomyomas, par-
ticularly variants, in the postmenopausal period.
Methods
We retrospectively reviewed data from women who
underwent surgery for uterine leiomyomas between
Received: January 11 2018.
Accepted: April 6 2018.
Correspondence: Dr Yuka Oi, Department of Obstetrics and Gynecology, Yokohama Municipal Citizen’s Hospital, 56 Okazawa-cho,
Hodogaya-ku, Yokohama 240-8555, Japan. Email: yukaoi56@ybb.ne.jp
1445© 2018 Japan Society of Obstetrics and Gynecology
doi:10.1111/jog.13675 J. Obstet. Gynaecol. Res. Vol. 44, No. 8: 1445–1450, August 2018
January 2007 and December 2014 at Yokohama
Municipal Citizen’s Hospital, Yokohama, Japan. We
evaluated clinical data including surgical indication,
parity, body mass index (BMI) and pathological
results, including the presence of endometriosis
and/or endometrial hyperplasia. The statistical analy-
sis was performed using STA13 (Light Stone) statisti-
cal analysis software. To compare intergroup patient
characteristics and data, Mann–Whitney U- and chi-
square tests were used for continuous and categorical
variables, respectively. This study was approved by
the Yokohama Municipal Citizen’s Hospital Institu-
tional Review Board and written informed consent
was waived because of the retrospective design.
Results
A total of 471 patients underwent surgery for uterine
leiomyomas at our hospital between January 2007
and December 2014. The highest incidence of leio-
myomas was observed in women aged 40–49 years
(63.9%), followed by women aged 30–39 (17.4%) and
those aged 50–59 years (13.4%). The incidence of leio-
myomas in women aged 60 years and above was
3.4% (Table 1). The mean patient age was 40.6 years,
while the median age was 45.0 years (range
24–81 years). Pelvic pressure was the primary surgical
indication among women aged 20–29, 30–39 and
60 years and above, while hypermenorrhea was the
primary indication for women aged 40–49 and
50–59 years. A suspicion of malignancy as the surgi-
cal indication was more common among women aged
50–59 or 60 years and above. There were no signiﬁ-
cant differences in the co-occurrence of endometriosis
or endometrial hyperplasia among the age groups.
Among the patients who underwent surgery for
leiomyomas, 6.4% (n = 30) were postmenopausal,
while 93.6% (n = 441) were premenopausal (Table 2).
Leiomyoma variants were observed in 21 patients:
11 lipoleiomyomas, ﬁve cellular leiomyomas, three
mitotically active leiomyomas, one intravenous leio-
myoma and one metastasizing leiomyoma (Table 2).
Therefore, the incidence of variants was 4.5% of the
leiomyomas, while lipoleiomyomas comprised 2.3%
of the leiomyomas. In common myomas, the inci-
dence of postmenopausal women was low (23/450,
5.1%). On the other hand, in variant type, the inci-
dence of postmenopausal patients was signiﬁcantly
higher than that of common myomas (7/21, 33.3%)
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most common surgical indication in cases of common
myomas, followed by pelvic pressure. In contrast, pel-
vic pressure was the most common surgical indication
in cases of variants. There were no signiﬁcant inter-
group differences in the frequency of the coincidence
with endometriosis or endometrial hyperplasia.
The incidence of variants was higher (7/30, 23.3%)
in postmenopausal patients than in premenopausal
patients (14/441, 3.2%) (Table 4). Six lipoleiomyomas
and one cellular leiomyoma were observed among
the postmenopausal patients with leiomyoma vari-
ants. More than half of the lipoleiomyomas (6/11,
54.5%) were found in the postmenopausal patients
(30 women), a ﬁgure that was signiﬁcantly higher
than the proportion of premenopausal patients
(441 women) with lipoleiomyomas (Table 5). The
mean age of patients with lipoleiomyomas tended to
be higher than that of those with variants, but statisti-
cally not signiﬁcant. No signiﬁcant differences were
observed in BMI, tumor size, frequency of complica-
tion with endometriosis or malignancy in the gyneco-
logical ﬁeld (Table 5).
All except one patient with a leiomyoma variant
had several nodules; the other had one nodule. All
except one of the nodules of the variant leiomyomas
were the largest tumors. One patient with lipoleio-
myoma had a history of treatment for gynecologic
malignancy (breast cancer).
Discussion
Uterine leiomyomas are known to appear after men-
arche, develop during the reproductive years and sta-
bilize or regress after menopause1; ovarian steroids
are believed to play a central role in leiomyoma
growth.4 This study revealed that the incidence of
surgically treated leiomyomas for women aged
50–59 years was 13.4%, while that for women aged
60 years and above was 3.4%. In a previous report,
the highest incidence of surgically removed uterine
leiomyomas was observed among women
40–49 years (46.7%), followed by those 50–59 years
(35.3%). It was also reported that, although myomas
were signiﬁcantly less common among post- than pre-
menopausal women, the incidence was still almost
10% among women aged 55–59 years and 10.3%
among women older than 60 years.2 Another study
analyzed 959 cases of surgically treated uterine myo-
mas and reported that the highest incidence was
observed among women aged 41–50 years (62.4%),
followed by women aged 51–60 years (18.8%) and
those 31–40 years (16.9%). The incidence for women
aged 20–30 years was 1.2%, while that for women
older than 60 years was 0.7%.3 These observations
indicate that considerable numbers of elderly patients,
who should have low levels of ovarian steroid hor-
mones, undergo surgery for uterine leiomyomas.
Progesterone rather than estrogen reportedly plays
a vital role in promoting leiomyoma growth.4 How-
ever, most leiomyomas identiﬁed early in pregnancy
remained the same even reduced in size over the
Table 2 Characteristics of patients who underwent
surgical treatment of uterine leiomyomas
Age (years)† 45.0 (24–81)
Body mass index (kg/m2)† 21.9 (15.4–42.9)
Before menopause 441 (93.6%)
After menopause 30 (6.4%)
Pathology, n = 471
Conventional type 450 (95.5%)
Variant type 21 (4.5%)
Lipoleiomyoma 11
Cellular leiomyoma 5
Mitotically active leiomyoma 3
Intravenous leiomyomatosis 1
Metastatic leiomyoma 1
†Values are given as median (range).
Table 3 Comparison of characteristics between common and variant uterine leiomyomas
Common type (n = 450) Variant type (n = 21) P value
Chief complaint
Pelvic pressure 203 (45.1%) 9 (42.9%) 0.839
Hypermenorrhea 238 (52.9%) 8 (38.1%) 0.185
Dysmenorrhea 58 (12.9%) 1 (4.8%) 0271
BMI† 22.7  3.59 23.1  3.31 0.496
Postmenopausal 23.5 (5.1%) 7 (33.3%) <0.001*
Comorbidity
Endometrosis 95 (21.1%) 4 (19.0%) 0.821
Endometrial hyperplasia 13 (2.9%) 1 (4.8%) 0.621
*P < 0.05. BMI, body mass index.
1447© 2018 Japan Society of Obstetrics and Gynecology
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course of pregnancy despite increased circulating con-
centrations of estrogen and progesterone.5 The effect
of the levonorgestrel-releasing intrauterine system on
leiomyoma size reportedly varies remarkably.6
Finally, leiomyomas are reportedly able to grow at
different rates over time and spontaneous regression
can occur at any age, not just after menopause.7 These
observations suggest that progesterone may have
dual actions on leiomyoma growth, both stimulating
and inhibiting it.4 Therefore, the primary cause of
leiomyoma growth after menopause may be this dual
action of progesterone.
Microscopic examinations of leiomyomas surgically
treated during the postmenopausal period showed
common histopathological features in most cases
(data not shown). We also previously reported that
lipoleiomyomas were the most common uterine vari-
ants among postmenopausal women requiring sur-
gery. Lipoleiomyomas primarily occur in the uterine
corpus of postmenopausal women.8 Fifty-eight
(82.8%) patients were reportedly postmenopausal in
an analysis of 70 consecutive women with 76 lipoleio-
myomas.9 These reports suggest that lipoleiomyomas
are relatively common leiomyoma variants among
postmenopausal women requiring surgical treatment.
The incidence of lipoleiomyomas was 0.35–2.9% of
leiomyomas and 0.28–2.1% of patients.8–12 In the cur-
rent study, the incidence of lipoleiomyomas among
leiomyoma patients was 2.3% (11/471). Therefore, our
ﬁndings seem consistent with previous results.
Of 76 (75.7%) patients with lipoleiomyomas, 53 had
different types associated with hyperestrogenic status
such as adenomyosis, endometriosis, endometrial
hyperplasia, polyps, complex atypical endometrial
hyperplasia and gynecologic carcinomas, suggesting
that estrogenic manifestations may be an important
factor in lipoleiomyoma development.9 On the other
hand, a case was reported in which the levels of cyto-
solic estrogen and progesterone receptors were lower
in the lipoleiomyoma than in the myometrium;
decreased steroid receptors was speculated to be
responsible for the lipomatous neometaplasia in this
tumor.8 It was also reported that the etiology of lipo-
leiomyomas may be related to the estrogen deﬁciency
that occurs after the menopausal transition.12 ln our
study, one patient with lipoleiomyomas had a history
of breast cancer (9.1%). In this study, the incidence of
endometriosis was 99 of the entire 471-patient cohort
(21.0%) and two of the 11 patients with lipoleiomyoma
(18.2%). Therefore, it is difﬁcult to speculate on the
relationship between lipoleiomyomas and estrogen,
and further studies are needed to understand it.
We found that all variant leiomyomas including
lipoleiomyomas occurred as single tumors except in
one case of two lipoleiomyomas. It was already
reported that lipoleiomyomas may rarely be multiple
but are often single with size variations.9 Cases of more
than two lipoleiomyomas have not been described in
the literature. The reason why uterine lipoleiomyomas
are rarely multiple is currently unknown.
In conclusion, uterine leiomyomas can grow or per-
sist after menopause, possibly because of the dual
actions of progesterone, and lipoleiomyomas are
important variants in the postmenopausal period. The
pathophysiology of uterine leiomyomas, including lipo-
leiomyomas, is not yet fully understood. Further stud-
ies are needed to better understand uterine leiomyomas
and explore new treatment strategies for them.
Acknowledgments
The authors express their deepest gratitude to Yone-
moto Naohiro, who provided helpful comments and
suggestions for analyzing the large number of samples.
Disclosure
None declared.
Table 5 Comparison of characteristics between lipoleiomyomas and other variants
Lipoleiomyomas (n = 11) Others (n = 10) P value
Age (years)† 56.1 (41–75) 46.5 (39–73) 0.083
Post menopausal 6 (54.5%) 1 (10.0%) 0.031*
BMI (kg/m2)† 23.4 (19.4–30.4) 22.8 (17.8–29) 0.724
Tumor size (cm)† 10.0 (2.0–30) 11.4 (4.0–30) 0.645
Suspected malignancy 1 (9.1%) 1 (10.0%) 0.943
Combination of endometriosis 2 (18.2%) 2 (20.0% ) 0.916
Gynecologic neoplasm 1 (9.1%) 0 (0%) 0.329
*P < 0.05. †Mean (range).
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